- Home
- VYGR
as 01-21-2025 4:00pm EST
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 342.5M | IPO Year: | 2015 |
| Target Price: | $15.53 | AVG Volume (30 days): | 361.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.47 | EPS Growth: | -62.72 |
| 52 Week Low/High: | $4.99 - $10.66 | Next Earning Date: | 02-26-2025 |
| Revenue: | $163,784,000 | Revenue Growth: | 3.40% |
| Revenue Growth (this year): | -62.92% | Revenue Growth (next year): | -20.10% |
Stock Insider Trading Activity of Voyager Therapeutics Inc. (VYGR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Swartz Robin | VYGR | COO & CBO | Jan 14 '25 | Sell | $5.09 | 3,087 | $15,712.83 | 109,241 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Jan 14 '25 | Sell | $5.13 | 1,191 | $6,109.83 | 86,436 | |
| Swartz Robin | VYGR | COO&CBO | Dec 23 '24 | Sell | $5.65 | 6,500 | $36,725.00 | 109,241 |
Latest Voyager Therapeutics Inc. News
VYGR Breaking Stock News: Dive into VYGR Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Cantor Fitzgerald Initiates Voyager Therapeutics at Overweight
Insider Monkey
24 days ago
Voyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now?
Zacks
a month ago
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
Simply Wall St.
a month ago
Institutional investors own a significant stake of 48% in Voyager Therapeutics, Inc. (NASDAQ:VYGR)
Zacks
2 months ago
Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High?
TipRanks
2 months ago
Wedbush upgrades Voyager to Outperform on pipeline progress
MT Newswires
2 months ago
Wedbush Upgrades Voyager Therapeutics to Outperform From Neutral, Raises Price Target to $11 From $7
MT Newswires
2 months ago
Voyager Therapeutics Selects Development Candidate for Tau Silencing Program in Alzheimer's Disease
Compare VYGR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VYGR Voyager Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.